How to Connect
Whether you have questions about what we do, are looking to partner with us, or are exploring options for clinical trials—please reach out using the form below that best describes the information you need.
To contact Verastem Product Information Center Call 1-877-VSTM-ONC
To report an Adverse Event or Product Complaint, please email email@example.com or fax toll-free 781-465-7936
Investigator Sponsored Trials (IST)
We believe in the power of collaboration to help us push forward with new and promising cancer treatments. Our Verastem Oncology Investigator Sponsored Trial (IST) program strives to advance medical and scientific knowledge for our product candidates and disease states of interest. We welcome partnerships with researchers and sponsoring institutions that build on this mission.
Investigator Sponsored Trial Form
For additional details regarding our IST program or to submit a research request, please download, complete and submit the form below via email to verastem-IST@verastem.com.
Verastem Oncology also accepts proposals for preclinical research collaborations. For more information, please reach out to us at firstname.lastname@example.org.
Verastem Oncology is a biopharmaceutical company committed to advancing new medicines for patients battling cancer, and we are also working to bring these medicines to patients as quickly and safely as possible. As both of our investigational agents, VS-6766 and defactinib, are in clinical trials to evaluate their efficacy and safety, we are not currently providing access to these therapies outside of clinical trials. At this time, we believe participation in a clinical trial is the optimal way to access these investigational therapies to enable thorough evaluation and support regulatory approvals. These ongoing clinical trials include the phase 2 registration-directed trials evaluating VS-6766 alone and in combination with defactinib, as part of our RAMP clinical development program (RAF And MEK Program), in patients with recurrent low-grade serous ovarian cancer (RAMP-201) and in patients with recurrent KRAS‑mutant non-small cell lung cancer (RAMP-202). More information about these trials is available at www.ramp201study.com and www.ramp202study.com. Individuals participating in our clinical trials are provided with the treatment being tested. The purpose of these trials is to determine whether the treatment is safe and effective. We submit a full complement of evidence from trials and other data to regulatory authorities, who make the final decision to approve the treatment or not. Until the regulatory authority has made this decision, the treatment remains experimental and not yet available to patients.
If you have questions about our programs or eligibility for our clinical trials, please contact us at email@example.com. A list of current clinical trials can be found at clinicaltrials.gov.